NASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Price, News & Analysis $10.02 +0.33 (+3.41%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About iTeos Therapeutics Stock (NASDAQ:ITOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iTeos Therapeutics alerts:Sign Up Key Stats Today's Range$9.59▼$10.0850-Day Range$9.69▼$17.9752-Week Range$8.20▼$18.75Volume445,192 shsAverage Volume413,002 shsMarket Capitalization$361.95 millionP/E RatioN/ADividend YieldN/APrice Target$30.50Consensus RatingBuy Company OverviewIteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.Read More… Next opportunity for crypto millions (Ad)October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…Go here to discover the coin that could define this historic bull run with gains kicking off this mo iTeos Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks64th Percentile Overall ScoreITOS MarketRank™: iTeos Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 404th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingiTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageiTeos Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about iTeos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.64) to ($5.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about iTeos Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.94% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in iTeos Therapeutics has recently decreased by 3.83%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.94% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in iTeos Therapeutics has recently decreased by 3.83%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment0.90 News SentimentiTeos Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for iTeos Therapeutics this week, compared to 1 article on an average week.Search Interest7 people have searched for ITOS on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows1 people have added iTeos Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iTeos Therapeutics' insider trading history. Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Stock News HeadlinesTANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics IncSeptember 30, 2024 | finance.yahoo.comInnate Pharma S.A. (IDD.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comNext opportunity for crypto millionsAs October unfolds and the effects of the Fed Pivot ripple through the market, this crypto could skyrocket. Want to know more?October 5, 2024 | Crypto 101 Media (Ad)Piper Sandler maintains Overweight rating on iTeos Therapeutics stockSeptember 18, 2024 | uk.investing.comITeos Therapeutics Shares Rise on Positive Data From Lung Cancer StudySeptember 17, 2024 | marketwatch.comiTeos Therapeutics (ITOS) Receives a Buy from Piper SandlerSeptember 17, 2024 | markets.businessinsider.comiTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGITSeptember 15, 2024 | seekingalpha.comBuy Rating Affirmed for iTeos Therapeutics Amid Promising Lung-201 Study OutcomesSeptember 14, 2024 | markets.businessinsider.comSee More Headlines ITOS Stock Analysis - Frequently Asked Questions How have ITOS shares performed this year? iTeos Therapeutics' stock was trading at $10.95 at the beginning of 2024. Since then, ITOS stock has decreased by 8.5% and is now trading at $10.02. View the best growth stocks for 2024 here. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced its earnings results on Thursday, August, 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.04) by $0.86. The firm had revenue of $35 million for the quarter, compared to the consensus estimate of $4.20 million. When did iTeos Therapeutics IPO? iTeos Therapeutics (ITOS) raised $151 million in an initial public offering on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? iTeos Therapeutics' top institutional shareholders include SG Americas Securities LLC (0.03%). Insiders that own company stock include Boxer Capital, Llc, Michel Detheux, Matthew Gall, Bioventures 2018 LP Mpm, Detlev Biniszkiewicz, David Hallal, Joanne Jenkins Lager, Ansbert Gadicke and Yvonne Mcgrath. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG) and Centene (CNC). Company Calendar Last Earnings8/08/2024Today10/05/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITOS CUSIPN/A CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$30.50 High Stock Price Target$46.00 Low Stock Price Target$21.00 Potential Upside/Downside+204.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,640,000.00 Net MarginsN/A Pretax Margin-292.80% Return on Equity-18.18% Return on Assets-15.86% Debt Debt-to-Equity RatioN/A Current Ratio18.08 Quick Ratio18.08 Sales & Book Value Annual Sales$35 million Price / Sales10.34 Cash FlowN/A Price / Cash FlowN/A Book Value$16.08 per share Price / Book0.62Miscellaneous Outstanding Shares36,123,000Free Float31,608,000Market Cap$361.95 million OptionableOptionable Beta1.39 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:ITOS) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.